| Drug General Information |
| Drug ID |
D0B7LK
|
| Former ID |
DIB001914
|
| Drug Name |
CY-1503
|
| Synonyms |
Cylexin
|
| Indication |
Hypertension [ICD9: 401; ICD10:I10-I16]
|
Phase 2/3 |
[1]
|
|---|
| Company |
Epimmune Inc
|
| CAS Number |
CAS 168678-84-0
|
| Target and Pathway |
| Target(s) |
P-selectin |
Target Info |
Modulator |
[2]
|
|---|
| E-selectin |
Target Info |
Modulator |
[2]
|
|
KEGG Pathway
|
Cell adhesion molecules (CAMs)
|
|
Malaria
|
|
Staphylococcus aureus infectionhsa04514:Cell adhesion molecules (CAMs)
|
|
TNF signaling pathway
|
|
African trypanosomiasis
|
|
NetPath Pathway
|
IL5 Signaling Pathway
|
|
IL4 Signaling Pathway
|
|
TNFalpha Signaling Pathway
|
|
ID Signaling Pathway
|
|
Pathway Interaction Database
|
IL4-mediated signaling events
|
|
amb2 Integrin signalingtxa2pathway:Thromboxane A2 receptor signaling
|
|
Glucocorticoid receptor regulatory network
|
|
ATF-2 transcription factor network
|
|
Reactome
|
Platelet degranulation
|
|
Cell surface interactions at the vascular wallR-HSA-202733:Cell surface interactions at the vascular wall
|
|
WikiPathways
|
Human Complement System
|
|
Spinal Cord Injury
|
|
Cell surface interactions at the vascular wallWP2806:Human Complement System
|
|
TNF alpha Signaling Pathway
|
|
Cell surface interactions at the vascular wall
|
| References |
| REF 1 | ClinicalTrials.gov (NCT00226369) Cylexin for Reduction of Reperfusion Injury in Infant Heart Surgery. U.S. National Institutes of Health. |
|---|
| REF 2 | Adjunctive selectin blockade successfully reduces infarct size beyond thrombolysis in the electrolytic canine coronary artery model. Circulation. 1995 Aug 1;92(3):492-9. |
|---|
